OBJECTIVE: To determine whether a specific apolipoprotein E (APOE) allele is a predictor for ischemic cerebrovascular disease (ICVD). BACKGROUND: The role of APOE in atherosclerosis has been a focus of intensive research. The APOE epsilon4 allele is overrepresented in Alzheimer's disease, atherosclerosis, ischemic heart disease, and ICVD. Also, epsilon4 carriers have higher cholesterol levels than non-epsilon4 carriers. METHODS: We performed a prospective, longitudinal study on patients who have ICVD. The patients were recruited from St. Mary Hospital, Korea, and investigated for ICVD through interviews and by reviewing their medical records and neuroimaging studies. APOE genotypes were determined for each patient. RESULTS: 20 of the 91 enrolled patients had recurrent ICVD, yielding a 3-year cumulative recurrence rate of 22%. Carriers of the epsilon4 allele had a 3-year recurrence rate of 53%, as compared with only 16% for patients who had the APOE non-epsilon4 allele (the risk ratio was 4.11; the 95% CI was 1.49-11.32; P<0.01). CONCLUSIONS: Our results make possible the identification of patients with ICVD who are at high risk for recurrence by assessing their APOE genotype. Also, this data might be clinically useful in methods for assessing potential strategies for prevention.
OBJECTIVE: To determine whether a specific apolipoprotein E (APOE) allele is a predictor for ischemic cerebrovascular disease (ICVD). BACKGROUND: The role of APOE in atherosclerosis has been a focus of intensive research. The APOE epsilon4 allele is overrepresented in Alzheimer's disease, atherosclerosis, ischemic heart disease, and ICVD. Also, epsilon4 carriers have higher cholesterol levels than non-epsilon4 carriers. METHODS: We performed a prospective, longitudinal study on patients who have ICVD. The patients were recruited from St. Mary Hospital, Korea, and investigated for ICVD through interviews and by reviewing their medical records and neuroimaging studies. APOE genotypes were determined for each patient. RESULTS: 20 of the 91 enrolled patients had recurrent ICVD, yielding a 3-year cumulative recurrence rate of 22%. Carriers of the epsilon4 allele had a 3-year recurrence rate of 53%, as compared with only 16% for patients who had the APOE non-epsilon4 allele (the risk ratio was 4.11; the 95% CI was 1.49-11.32; P<0.01). CONCLUSIONS: Our results make possible the identification of patients with ICVD who are at high risk for recurrence by assessing their APOE genotype. Also, this data might be clinically useful in methods for assessing potential strategies for prevention.
Authors: Jessica M Foley; David H Salat; Nikki H Stricker; Tyler A Zink; Laura J Grande; Regina E McGlinchey; William P Milberg; Elizabeth C Leritz Journal: Am J Alzheimers Dis Other Demen Date: 2013-12-31 Impact factor: 2.035
Authors: E J Heyer; D A Wilson; D H Sahlein; J Mocco; S C Williams; R Sciacca; A Rampersad; R J Komotar; J Zurica; A Benvenisty; D O Quest; G Todd; R A Solomon; E S Connolly Journal: Neurology Date: 2005-10-05 Impact factor: 9.910
Authors: Jessica M Foley; David H Salat; Nikki H Stricker; Regina E McGlinchey; William P Milberg; Laura J Grande; Elizabeth C Leritz Journal: Am J Alzheimers Dis Other Demen Date: 2015-05-24 Impact factor: 2.035
Authors: Philip L De Jager; Joshua M Shulman; Lori B Chibnik; Brendan T Keenan; Towfique Raj; Robert S Wilson; Lei Yu; Sue E Leurgans; Dong Tran; Cristin Aubin; Christopher D Anderson; Alessandro Biffi; Jason J Corneveaux; Matthew J Huentelman; Jonathan Rosand; Mark J Daly; Amanda J Myers; Eric M Reiman; David A Bennett; Denis A Evans Journal: Neurobiol Aging Date: 2011-11-04 Impact factor: 4.673